Despite survival improvements achieved over the last two decades, prostate cancer remains
lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches …

Poly-ADP ribose polymerase inhibitors (PARPi) are an emerging therapeutic option for the
treatment of prostate cancer. Their primary mechanism of action is via induction of synthetic …

Background The prognostic significance of germline variants in homologous recombination
repair genes in advanced prostate cancer (PCa), especially with regard to hormonal …

Purpose: To study associations across tumor types between genome-wide loss of
heterozygosity (gLOH) and alterations in homologous recombination repair (HRR) …

Simple Summary Several strategies have demonstrated the ability to improve the survival of
patients with both metastatic and nonmetastatic prostate cancer. The old backbone of …

Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the
past decade, several new treatments for advanced prostate cancer have been approved …

Many clinical decisions in oncology practice rely on the presence or absence of an alteration
in a single genetic locus, be it a pathogenic variant in a hereditary cancer gene or activating …

Context Testing for mutations in Breast Cancer Gene 1/2 (BRCA) has emerged as a novel
decision-making tool for clinicians. Patients with metastatic castration-resistant prostate …

The treatment of metastatic castration-resistant prostate cancer (mCRPC) has been
fundamentally transformed by our greater understanding of its complex biological …

Simple Summary In our study, we found genetic mutations in the DNA of cancer cells
obtained from the blood of many patients with metastatic prostate cancer. These changes …